Latest Articles

From detecting cancer to microbial infections, and now even fungal infections, PCR has become the gold standard of analyzing gene expression. In this article, we explore how PCR is used as a novel diagnostic strategy to identify clinically important yeast species, as well as to detect mutations that could guide therapeutic decisions for lung cancer patients.

From optimizing immunotherapy to second-guessing cancer’s next evolutionary step – there has never been a more innovative era in cancer drug discovery.

Could therapies targeting our immune system help treat Alzheimer's disease by flipping long-standing research theories on their head? A new drug targeting a two-faced protein is currently undergoing clinical trials to find an answer.

What do we mean by lab of the future? What innovations are required to get there? These are the key themes explored by this year's Lab of the Future Congress, summarized in this article.

In this feature of Technology Networks Explores the CRISPR Revolution, we interview Professor Glenn Cohen, director of Harvard Law School's Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics.

Flow cytometry has inarguable potential as a clinical tool for disease diagnosis, prognosis, and therapeutic monitoring. However, some challenges remain in translating the full promise of FCM into clinical practice. Here, some of the current clinical applications of FCM will be discussed, as well as some of the compelling new applications being researched.

Recent research has shown that modifiable factors, such as our microbiome diversity, have a much more significant effect on many of our responses to food than fixed factors, like age or genetics. To learn more about predicting and modifying responses to food we spoke with Professor Tim Spector, expert on personalized nutrition.

In this feature of "Technology Networks Explores the CRISPR Revolution", Professor George Church lends his views on some of the milestones achieved in genomics research to date, elaborates on "that wooly mammoth study" and emphasizes his desire to make genomic technologies more widely available.

Technology Networks spoke with the world-renowned scientist and 2020 Nobel Prize in Chemistry winner Professor Jennifer Doudna, the co-developer of CRISPR genome editing technology.

A pair of recent studies looked at the reliability of clinical observations and bacterial culture versus quantitative PCR (qPCR) in detecting clinically healthy carriers of the bacterium that causes strangles, who pose an infection risk to naïve individuals.